ABSTRACT
BACKGROUND: Although immune-checkpoint inhibitors (ICI) are overall promissory for cancer treatment, they entail, in some cases, an undesired side-effect called hyperprogressive-cancer disease (HPD) associated with acceleration of tumor growth and shortened survival. METHODS: To understand the mechanisms of HPD we assayed the ICI therapy on two murine tumors widely different regarding immunogenicity and, subsequently, on models of local recurrences and metastases of these tumors. To potentiate the immune response (IR), we combined ICI with meta-tyrosine-that counteracts immune-suppressive signals-and a selective inhibitor of p38 pathway that proved to counteract the phenomenon of tumor-immunostimulation. RESULTS: ICI were therapeutically effective against both tumor models (proportionally to their immunogenicity) but only when they faced incipient tumors. In contrast, ICI produced acceleration of large and residual tumors. The combined treatment strongly inhibited the growth of large tumors and it managed to cure 80% of mice with local recurrences and 60% of mice bearing residual metastases. CONCLUSIONS: Tumor enhancement was paradoxically correlated to a weak increase of the antitumor IR suggesting that a weak IR - different from a strong tumor-inhibitory one-may produce stimulation of tumor growth, mimicking the HPD observed in some clinical settings.
Subject(s)
Immune Checkpoint Inhibitors , Neoplasms , Animals , Disease Progression , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Mice , Neoplasms/drug therapy , TyrosineABSTRACT
PURPOSE: The use of methadone for cancer pain is limited by the need of expertise and close titration due to variable half-life. Yet, it is a helpful palliative strategy in low-resources countries given its long-acting effect at low cost and worth additional study. Our aim was to describe the prescription and outcomes of methadone as a first-line treatment for cancer pain in a tertiary palliative care unit (PCU) in Argentina. METHODS: Retrospective review of medical records of patients with moderate to severe cancer pain seen at the PCU in 1-year period, who initiated strong opioids at the first consultation. Data collected during the first month of treatment included disease and pain characteristics, initial and final opioid type and dose and need for opioid rotation. RESULTS: Methadone was the most frequent opioid both at the initial and last assessment (71 and 66 % of the prescriptions). In all, treatment with strong opioids provided considerable decrease in pain intensity (p < 0.001) with low and stable opioid dose. Median and interquartile range (IR) of oral morphine equivalent daily dose (OMEDD) was 26 (16-32) and 39 (32-55) mg for initial and final assessments, respectively (p = 0.3). In patients initiated with methadone, the median (IR) daily methadone dose was 5 (4-6) mg at first and 7.5 (6-10) mg at final assessment, and the median (IR) index of opioid escalation was 0 (0-4) mg; (p < 0.05). Patients on methadone underwent less percentage of opioid rotation (15 versus 50 %; p < 0.001) and longer time to rotation (20.6 ± 4.4 versus 9.0 ± 2.7 days; p < 0.001) than patients on other opioids. CONCLUSIONS: Results indicate the preference of methadone as first-line strong opioid treatment in a PCU, providing good pain relief at low doses with low need for rotation. Several considerations about the costs of strong opioids in the region are given.
Subject(s)
Analgesics, Opioid/therapeutic use , Cancer Pain/drug therapy , Methadone/therapeutic use , Neoplasms/complications , Pain Measurement/methods , Palliative Care/methods , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/pharmacology , Developing Countries , Female , Humans , Male , Methadone/administration & dosage , Methadone/pharmacology , Middle Aged , Neoplasms/drug therapy , Retrospective StudiesABSTRACT
Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. While former studies have indicated that T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifestation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. In this work, we have extended our previous findings demonstrating that a periodic intravenous administration of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two different metastatic murine tumors and decreased the rate of death from 100% up to 25% in tumor-excised mice that already exhibited established metastases at the time of surgery. These anti-metastatic effects were achieved even at very low concentrations and without displaying any detectable toxic-side effects, suggesting that the use of meta-tyrosine may help to develop new and less harmful means of managing malignant diseases, especially those aimed to control the growth of metastases that is the most serious problem in cancer pathology.
Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma/pathology , Carcinoma/prevention & control , Liver Neoplasms/prevention & control , Lung Neoplasms/prevention & control , Mammary Neoplasms, Experimental/pathology , Tyrosine/administration & dosage , Animals , Antineoplastic Agents/blood , Antineoplastic Agents/chemistry , Dose-Response Relationship, Drug , Isomerism , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Mice, Inbred BALB C , Tyrosine/adverse effects , Tyrosine/chemistryABSTRACT
In cancer, B cells have been classically associated with antibody secretion, antigen presentation and T cell activation. However, a possible role for B lymphocytes in impairing antitumor response and collaborating with tumor growth has been brought into focus. Recent reports have described the capacity of B cells to negatively affect immune responses in autoimmune diseases. The highly immunogenic mouse tumor MCC loses its immunogenicity and induces systemic immune suppression and tolerance as it grows. We have previously demonstrated that MCC growth induces a distinct and progressive increase in B cell number and proportion in the tumor draining lymph nodes (TDLN), as well as a less prominent increase in T regulatory cells. The aim of this research was to study B cell characteristics and function in the lymph node draining MCC tumor and to analyze whether these cells may be playing a role in suppressing antitumor response and favoring tumor progression. Results indicate that B cells from TDLN expressed increased CD86 and MHCII co-stimulatory molecules indicating activated phenotype, as well as intracellular IL-10, FASL and Granzyme B, molecules with regulatory immunosuppressive properties. Additionally, B cells showed high inhibitory upon T cell proliferation ex vivo, and a mild capacity to secrete antibodies. Our conclusion is that even when evidence of B cell-mediated activity of the immune response is present, B cells from TDLN exhibit regulatory phenotype and inhibitory activity, probably contributing to the state of immunological tolerance characteristic of the advanced tumor condition.
Subject(s)
Antigens, Neoplasm/immunology , B-Lymphocytes, Regulatory/immunology , Immune Tolerance/immunology , Lymph Nodes/immunology , Sarcoma/immunology , Animals , Cell Count , Cell Line, Tumor , Cell Proliferation/physiology , Flow Cytometry , Lymph Nodes/pathology , Mice, Inbred BALB C , Phenotype , Sarcoma/pathology , T-Lymphocytes, Regulatory/immunologyABSTRACT
Histopathological features of hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DEN) in mice display strong similarities with those seen in humans, including the higher tumor prevalence in males than in females. Previous studies have demonstrated that continual production of the pro-inflammatory IL-6 by Kupffer cells is involved in the initiation and progression of DEN-induced HCC and that estrogen-mediated reduction of IL-6 secretion would decrease its incidence in females. Given the predominant utilization of male mice in hepatic carcinogenesis research, the objective of this study was to examine histopathological and immunological parameters in the DEN-induced liver carcinogenesis model in female C3H mice. We observed a significant prevalence of hepatocellular hyperplasias and adenomas alongside a minimal infiltration of inflammatory cells and a scarcity of senescent areas in females. Further, a low expression of immunosuppression markers is observed in females - such as neutrophil/lymphocyte ratio, PD-1 expression in CD8 T cells, and PD-L1 in myeloid cells - compared to males. Comparative studies between susceptible and resistant hosts to chemical carcinogenesis may help to unveil novel therapeutic strategies against cancer.
ABSTRACT
Tumor-draining lymph node (TDLN) ablation is routinely performed in the management of cancer; nevertheless, its usefulness is at present a matter of debate. TDLN are central sites where T cell priming to tumor antigens and onset of the antitumor immune response occur. However, tumor-induced immunosuppression has been demonstrated at TDLN, leading to downregulation of antitumor reaction and tolerance induction. Tolerance in turn is a main impairment for immunotherapy trials. We used a murine immunogenic fibrosarcoma that evolves to a tolerogenic state, to study the cellular and molecular mechanisms underlying tolerance induction at the level of TDLN and to design an appropriate immunotherapy. We determined that following a transient activation, the established tumor induces signs of immunosuppression at TDLN that coexist with local and systemic evidences of antitumor response. Therefore, we evaluated the feasibility of removing TDLN in order to eliminate a focus of immunosuppression and favor tumor rejection; but instead, a marked exacerbation of tumor growth was induced. Combining TDLN ablation with the in vivo depletion of regulatory cells by low-dose cyclophosphamide and the restoring of the TDLN-derived cells into the donor mouse by adoptive transference, resulted in lowered tumor growth, enhanced survival and a considerable degree of tumor regression. Our results demonstrate that important antitumor elements can be eliminated by lymphadenectomy and proved that the concurrent administration of low-dose chemotherapy along with the reinoculation of autologous cytotoxic cells provides protection. We suggest that this protocol may be useful, especially in the cases where lymphadenectomy is mandatory.
Subject(s)
Adoptive Transfer , Antineoplastic Agents, Alkylating/therapeutic use , Cyclophosphamide/therapeutic use , Fibrosarcoma/therapy , Immunotherapy, Adoptive , Lymph Node Excision , T-Lymphocytes, Cytotoxic/transplantation , Animals , Combined Modality Therapy , Fibrosarcoma/drug therapy , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , T-Lymphocytes, Cytotoxic/immunologyABSTRACT
There is a rather generalized belief that the worst possible outcome for the application of immunological therapies against cancer is a null effect on tumor growth. However, a significant body of evidence summarized in the immunostimulatory hypothesis of cancer suggests that, upon certain circumstances, the growth of incipient and established tumors can be accelerated rather than inhibited by the immune response supposedly mounted to limit tumor growth. In order to provide more compelling evidence of this proposition, we have explored the growth behavior characteristics of twelve murine tumors -most of them of spontaneous origin- arisen in the colony of our laboratory, in putatively immunized and control mice. Using classical immunization procedures, 8 out of 12 tumors were actually stimulated in "immunized" mice while the remaining 4 were neither inhibited nor stimulated. Further, even these apparently non-antigenic tumors could reveal some antigenicity if more stringent than classical immunization procedures were used. This possibility was suggested by the results obtained with one of these four apparently non-antigenic tumors: the LB lymphoma. In effect, upon these stringent immunization pretreatments, LB was slightly inhibited or stimulated, depending on the titer of the immune reaction mounted against the tumor, with higher titers rendering inhibition and lower titers rendering tumor stimulation. All the above results are consistent with the immunostimulatory hypothesis that entails the important therapeutic implications -contrary to the orthodoxy- that, anti-tumor vaccines may run a real risk of doing harm if the vaccine-induced immunity is too weak to move the reaction into the inhibitory part of the immune response curve and that, a slight and prolonged immunodepression -rather than an immunostimulation- might interfere with the progression of some tumors and thus be an aid to cytotoxic therapies.
Subject(s)
Antineoplastic Agents/immunology , Cancer Vaccines/immunology , Neoplasms, Experimental/immunology , Animals , Antineoplastic Agents/therapeutic use , Disease Models, Animal , Disease Progression , Female , Immunization , Lymphoma/immunology , Lymphoma/pathology , Mice , Mice, Inbred BALB C , Neoplasms, Experimental/pathology , Neoplasms, Experimental/therapyABSTRACT
Sepsis is characterized by an early pro-inflammatory phase followed by compensatory anti-inflammatory mechanisms that lead to a late generalized immunosuppression, period where most deaths occur. Immunotherapy approaches to recover the immunocompetence in sepsis are similar to those used in cancer. Meta-tyrosine (m-Tyr) is a product of oxidative stress present in circulation during the sepsis and cancer-associated pro-inflammatory stages. In this work, considering its potential participation in pro-inflammatory processes, we evaluate the effect of m-Tyr during LPS induced immunosuppression phase in a murine model. In addition, we examine the effect of m-Tyr in a vaccination strategy using a weakly immunogenic tumor model. Our results showed that m-Tyr could prevent the establishment of immunosuppression and rescue the host from an installed immunosuppression induced by LPS. These effects were parallel to the ability of m-Tyr to improve the pro-inflammatory effects induced by LPS and inhibit the anti-inflammatory action of dexamethasone. Also, m-Tyr treatment prevents both the reduction of splenic lymphocytes and the increase of the expression of programmed death ligand-1 in splenic myeloid cells associated with immunosuppression. Besides, treatment with m-Tyr increased the protective effect of an anti-tumor vaccine, suggesting that m-Tyr could improve the immune response. In summary, we suggest that m-Tyr can modulate critical immunological indicators through the inflammatory context, which could improve the management of diseases, such as sepsis and cancer, in which immunosuppression is a significant clinical problem.
Subject(s)
Cancer Vaccines/immunology , Immunologic Factors/therapeutic use , Mammary Neoplasms, Animal/therapy , Myeloid-Derived Suppressor Cells/physiology , Sepsis/therapy , Tyrosine/therapeutic use , Animals , B7-H1 Antigen/antagonists & inhibitors , Cell Line, Tumor , Disease Models, Animal , Female , Gene Expression Regulation, Neoplastic , Humans , Lipopolysaccharides/immunology , Mammary Neoplasms, Animal/immunology , Mice , Mice, Inbred BALB C , Myeloid-Derived Suppressor Cells/drug effects , Neoplasm Metastasis , Sepsis/immunologyABSTRACT
Up to date, most attempts to use immunotherapy to cause the regression of animal and human established tumors have not been successful. Former experiments have postulated that this failure could be attributed, at least in part, to a lack of immunogenicity of spontaneous tumors. In this paper, we have investigated whether this lack of immunogenicity can be attributed to the absence of tumor antigens or to the existence of tolerogenic mechanisms preventing such antigens from initiating an antitumor immune response. We have used two murine tumors a non-immunogenic spontaneous lymphoma (LB) and a strongly immunogenic methylcholanthrene-induced fibrosarcoma (MC-C) together with a vaccination strategy based on the inoculation of dendritic cells (DC) loaded with a tumor lysate. When DC were pulsed with LB lysate (DC+LB), no maturation of DC was achieved in vitro and no protection against LB implants after DC+LB inoculation was observed in vivo. On the other hand, when DC were pulsed with MC-C lysate (DC+MC-C), maturation of DC was observed along with a strong protection against MC-C implants after DC+MC-C inoculaton. Finally, when DC were pulsed with both LB and MC-C lysates (DC+LB+MC-C), maturation of DC and protection against LB implants were achieved. Since no immune cross reaction between MC-C and LB was ever observed, the most likely interpretation is that LB bears specific tumor antigens but lacks other signals to achieve DC maturation. These signals would be provided by MC-C which would enable DC to mature and to initiate an effective anti-LB immune response.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Dendritic Cells/immunology , Fibrosarcoma/immunology , Lymphoma, B-Cell/immunology , Animals , Biomarkers, Tumor , Cancer Vaccines/therapeutic use , Disease Models, Animal , Fibrosarcoma/chemically induced , Immunotherapy/methods , Lymphoma, B-Cell/chemically induced , Mice , Mice, Inbred BALB CABSTRACT
Immune-checkpoint inhibitors and antitumor vaccines may produce both tumor-inhibitory and tumor-stimulatory effects on growing tumors depending on the stage of tumor growth at which treatment is initiated. These paradoxical results are not necessarily incompatible with current tumor immunology but they might better be explained assuming the involvement of the phenomenon of tumor immunostimulation. This phenomenon was originally postulated on the basis that the immune response (IR) evoked in Winn tests by strong chemical murine tumors was not linear but biphasic, with strong IR producing inhibition and weak IR inducing stimulation of tumor growth. Herein, we extended those former observations to weak spontaneous murine tumors growing in pre-immunized, immune-competent and immune-depressed mice. Furthermore, we demonstrated that the interaction of specifical T cells and target tumor cells at low stimulatory ratios enhanced the production of chemokines aimed to recruit macrophages at the tumor site, which, upon activation of toll-like receptor 4 and p38 signaling pathways, would recruit and activate more macrophages and other inflammatory cells which would produce growth-stimulating signals leading to an accelerated tumor growth. On this basis, the paradoxical effects achieved by immunological therapies on growing tumors could be explained depending upon where the therapy-induced IR stands on the biphasic IR curve at each stage of tumor growth. At stages where tumor growth was enhanced (medium and large-sized tumors), counteraction of the tumor-immunostimulatory effect with anti-inflammatory strategies or, more efficiently, with selective inhibitors of p38 signaling pathways enabled the otherwise tumor-promoting immunological strategies to produce significant inhibition of tumor growth.
ABSTRACT
An abrupt increase in metastatic growth as a consequence of the removal of primary tumors suggests that the concomitant resistance (CR) phenomenon might occur in human cancer. CR occurs in murine tumors and ROS-damaged phenylalanine, meta-tyrosine (m-Tyr), was proposed as the serum anti-tumor factor primarily responsible for CR. Herein, we demonstrate for the first time that CR happens in different experimental human solid tumors (prostate, lung anaplastic, and nasopharyngeal carcinoma). Moreover, m-Tyr was detected in the serum of mice bearing prostate cancer (PCa) xenografts. Primary tumor growth was inhibited in animals injected with m-Tyr. Further, the CR phenomenon was reversed when secondary implants were injected into mice with phenylalanine (Phe), a protective amino acid highly present in primary tumors. PCa cells exposed to m-Tyr in vitro showed reduced cell viability, downregulated NFκB/STAT3/Notch axis, and induced autophagy; effects reversed by Phe. Strikingly, m-Tyr administration also impaired both, spontaneous metastasis derived from murine mammary carcinomas (4T1, C7HI, and LMM3) and PCa experimental metastases. Altogether, our findings propose m-Tyr delivery as a novel approach to boost the therapeutic efficacy of the current treatment for metastasis preventing the escape from tumor dormancy.
Subject(s)
Neoplasm Metastasis/pathology , Phenylalanine/metabolism , Reactive Oxygen Species/metabolism , Animals , Cell Line, Tumor , Cell Proliferation , Down-Regulation , Drug Resistance, Neoplasm , Humans , Male , Mice, Nude , Prostatic Neoplasms/pathology , Serum , Signal Transduction , Subcutaneous Tissue/pathology , Tyrosine/metabolism , Xenograft Model Antitumor AssaysABSTRACT
The link between cancer and inflammation in an organ or tissue has firmly been established on the basis that cancer tends to occur at sites of chronic inflammation and that local inflammatory processes can accelerate the growth of preexisting tumors in both animals and human beings. In contrast, the relationship between cancer and systemic inflammation has been less studied. In this work, we demonstrated that the growth of the murine fibrosarcoma MC-C, was accompanied by manifestations of systemic inflammation, as demonstrated by an increase in both the number of circulating polymorphonuclear neutrophils (PMN) and the serum concentration of the proinflammatory cytokines interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and the acute phase proteins C reactive (CRP) and serum A amyloid (SAA). Two temporally separate peaks of systemic inflammation were detected during tumor development. The first was displayed during the first week after tumor inoculation. The second peak began around day 14 and its intensity was proportional to tumor size. In mice bearing a large MC-C tumor, a high number of circulating PMN and myeloid precursors were evident. Most of these cells exhibited activation evidenced by an increased reactive oxygen species generation and high expression of the Gr1+/Mac1+ markers. Inoculation of thioglycolate -which generates a transient systemic inflammation-accelerated the growth of MC-C tumor and reciprocally, inhibition of such systemic inflammation by using indomethacin, prevented that enhancing effect. This suggests that the systemic inflammation that the tumor generates on its own, could be part of its growth strategy.
Subject(s)
Biomarkers, Tumor/blood , Cytokines/blood , Fibrosarcoma/pathology , Inflammation/pathology , Neoplasms, Experimental/pathology , Animals , Fibrosarcoma/blood , Inflammation/blood , Interleukin-1beta/blood , Mice , Mice, Inbred BALB C , Models, Animal , Reactive Oxygen Species/analysis , Reactive Oxygen Species/blood , Serum Amyloid A Protein/analysis , Tumor Necrosis Factor-alpha/bloodABSTRACT
Although animals can be prophylactically immunized against the growth of tumor implants, most of the attempts to use immunotherapy to cause the regression of animal and human tumors once they become established have been unsuccessful. To understand the nature of this refractoriness we have studied a methylcholanthrene-induced and strongly immunogenic murine fibrosarcoma. In our model, the onset of this refractoriness was associated with the beginning of an immunosuppressive state known as "immunological eclipse" characterized by a loss of the antitumor immune response when tumor grows beyond a critical size. This immunological eclipse was accompanied by the emergence of a systemic inflammatory condition. Treatment of tumor-bearing mice with a single dose of a synthetic corticosteroid, dexamethasone (DX), reduced significantly all parameters of systemic inflammation and simultaneously reversed the immunological eclipse. The reversion of the eclipse upon DX treatment was not curative itself, but allowed an immunological therapy based in dendritic cells pulsed with tumor antigens, which was itself absolutely ineffective, to exert a significant inhibitory effect against an established growing tumor. The two-step schedule using an anti-inflammatory treatment to reverse the immunological eclipse plus a dendritic cell-based vaccination strategy aimed to stimulate the antitumor immune response, could serve eventually as a model of immunotherapy against animal and human tumors.
Subject(s)
Cancer Vaccines/therapeutic use , Dendritic Cells/immunology , Fibrosarcoma/drug therapy , Immune Tolerance/immunology , Sarcoma, Experimental/drug therapy , Animals , Anti-Inflammatory Agents/immunology , Anti-Inflammatory Agents/therapeutic use , Cancer Vaccines/immunology , Carcinogens , Dexamethasone/immunology , Dexamethasone/therapeutic use , Disease-Free Survival , Fibrosarcoma/chemically induced , Fibrosarcoma/immunology , Immune Tolerance/drug effects , Inflammation/drug therapy , Methylcholanthrene , Mice , Mice, Inbred BALB C , Sarcoma, Experimental/chemically induced , Sarcoma, Experimental/immunologyABSTRACT
Despite the classic role of B cells in favoring the immune response, an inhibitory action of B lymphocytes in tumor immunity has emerged in certain studies. In methylcolanthrene-induced murine fibrosarcoma (MCC), the loss of immunogenicity and the establishment of tolerance are paralleled by systemic immune suppression and the appearance of B+IL-10+ cells in tumor-draining lymph nodes. The present study aimed to assess the role of the B+IL-10+ cell population in the immune evasion and tolerance induced by MCC through the depletion of B cells in mice at various times of tumor progression: Prior to or subsequent to tumor implantation. Tumor growth and immunological parameters were evaluated. B cell depletion prior to tumor inoculum enhanced tumor growth, initiating the onset of the tumor-induced systemic immune response; however, an increase in the T regulatory cells (Tregs) at the tumor-draining lymph node could account for tumor exacerbation. B cell depletion once the tumor was established resulted in decreased tumor growth and a delayed onset of tolerance. Additionally, B cell absence exacerbated T cell dependent-tumor rejection, reduced Tregs and increased cytotoxic CD8+ T cells. In vitro analysis showed a direct effect of B cells upon T cell proliferation. In conclusion, B cell depletion exerts opposite effects when performed prior to or subsequent to tumor implantation. In this initially immunogenic tumor, B cell absence would delay the establishment of immunological tolerance probably by unmasking a pre-existing antitumor response. The present findings elucidate the convenience of modulating B cells in the development of future and more effective immunotherapies against cancer.
ABSTRACT
BACKGROUND: Most theories about cancer proposed during the last century share a common denominator: cancer is believed to be a biological nonsense for the organism in which it originates, since cancer cells are believed to be ones evading the rules that control normal cell proliferation and differentiation. In this essay, we have challenged this interpretation on the basis that, throughout the animal kingdom, cancer seems to arise only in injured organs and tissues that display lost or diminished regenerative ability. HYPOTHESIS: According to our hypothesis, a tumor cell would be the only one able to respond to the demand to proliferate in the organ of origin. It would be surrounded by "normal" aged cells that cannot respond to that signal. According to this interpretation, cancer would have a profound biological sense: it would be the ultimate way to attempt to restore organ functions and structures that have been lost or altered by aging or noxious environmental agents. In this way, the features commonly associated with tumor cells could be reinterpreted as progressively acquired adaptations for responding to a permanent regenerative signal in the context of tissue injury. Analogously, several embryo developmental stages could be dependent on cellular damage and death, which together disrupt the field topography. However, unlike normal structures, cancer would have no physiological value, because the usually poor or non-functional nature of its cells would make their reparative task unattainable. CONCLUSION: The hypothesis advanced in this essay might have significant practical implications. All conventional therapies against cancer attempt to kill all cancer cells. However, according to our hypothesis, the problem might not be solved even if all the tumor cells were eradicated. In effect, if the organ failure remained, new tumor cells would emerge and the tumor would reinitiate its progressive growth in response to the permanent regenerative signal of the non-restored organ. Therefore, efficient anti-cancer therapy should combine an attack against the tumor cells themselves with the correction of the organ failure, which, according to this hypothesis, is fundamental to the origin of the cancer.
Subject(s)
Cell Differentiation , Cell Proliferation , Neoplasms/physiopathology , Adaptation, Physiological , Cellular Senescence , Embryonic Development , Humans , Neoplasms/therapyABSTRACT
A small primary or secondary tumor load can occasionally induce more deleterious effects than a histologically identical larger one. In the four murine models studied herein this enhanced tumor aggressiveness could not be attributed to NRAS mutations or other hereditary changes, differential vascularization of live tumor tissues, or necrosis content. Instead, the main tumor feature associated with a more aggressive behavior was the presence of a high number of vessels, sometimes filled with inflammatory cells, inside a tumor area, which we have identified and designated as the transition zone between the live and the necrotic zones. Our experiments suggest that during tumor growth, different cachectic factors are produced within the transition and necrotic zones by dying tumor cells and by tumor infiltrating macrophages only reaching the general circulation through the vessels present in the transition zone. Therefore, a small tumor displaying high vascularization of its transition area could be harmful to its host, while, in contrast, a large tumor could behave as a relatively benign one if its transition zone exhibited little or no vascularization, and in consequence its cachectic factors remained "trapped." Similar histological images to those observed in mice were seen in a significant percentage of human cancer biopsies, raising the possibility that such images might have a prognostic value.
Subject(s)
Neoplasms/pathology , Neovascularization, Pathologic/pathology , Animals , Biomarkers, Tumor/analysis , Cell Line, Tumor , DNA, Neoplasm/analysis , Female , Humans , Male , Mice , Mice, Inbred BALB C , Mutation , Necrosis , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Transplantation , Neoplasms/blood supply , Neoplasms/genetics , Neoplasms/metabolism , Proto-Oncogene Proteins/genetics , RNA, Neoplasm/analysis , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
A differential effect of pregnancy on the growth of subcutaneous implants of four murine tumors has been observed. Two tumors lacking receptors for progesterone and estrogen [methylcholanthrene-induced fibrosarcoma (MC-C) and spontaneous lymphoid leukemia (LB)] exhibited slow kinetics throughout the course of pregnancy, although inhibition was stronger beyond day 10. On the other hand, one of two tumors bearing receptors for progesterone and estrogen [medroxyprogesterone (MPA)-induced mammary adenocarcinoma (C7HI)] exhibited three phases: up to days 8-10 of gestation the tumor grew faster than in virgins, between days 8-10 and 15 it reached a plateau, and beyond day 15 a sharp reduction in tumor mass was observed. The other tumor [mouse mammary tumor virus (MMTV)-induced mammary carcinoma(T2280)] behaved as a typical pregnancy-dependent tumor (i.e., it grew in pregnant but not in virgin mice, regressed soon after delivery, and reassumed its growth at the middle of a second round of pregnancy). Neither MPA nor estrogen affected MC-C and LB tumor growth. On the other hand, MPA-treated mice enhanced C7HI tumor and reciprocally C7HI tumor-bearing mice treated with estrogen strongly inhibited tumor growth. As for T2280, neither MPA nor estrogen alone could promote tumor growth and, in consequence, no tumor developed. However, when MPA plus estrogen was administered in a schedule simulating the successive appearance of these hormones in pregnancy, T2280 grew even faster than in pregnant mice. When the four tumors were implanted in mice bearing grafts of embryonal tissues (teratomas), all of them were inhibited. This antitumor effect was similar to that observed in pregnancy when tumors unresponsive to progesterone and estrogen were tested. On the other hand, with tumors bearing progesterone and estrogen receptors, differences in tumor growth were detected in pregnant and teratoma-bearing mice. This suggested the existence during pregnancy of two factors potentially acting on tumor growth. First, a progesterone and estrogen-mediated hormonal component, which would exert either inhibitory or stimulatory effects only evidenced with tumors bearing hormonal receptors. Secondly, an antitumor effect proportional to the growing embryonal mass, inhibiting all tumors independently of their origin or hormone responsiveness. This antitumor effect could be attributed to a beat-resistant serum factor (1,000-1,200 Da molecular weight) presumably associated with the pathway of the arachidonic acid metabolism. The interplay between the hormonal component and the serum factor associated with embryonal mass could account for some of the largely heterogeneous and otherwise unexplained effects of pregnancy on tumor growth reported in the literature and illustrated by the four tumors studied here.
Subject(s)
Hormones/physiology , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/physiopathology , Pregnancy Complications, Neoplastic/physiopathology , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/physiopathology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cell Division/drug effects , Cell Division/physiology , Estrogens/pharmacology , Female , Fibrosarcoma/drug therapy , Fibrosarcoma/pathology , Fibrosarcoma/physiopathology , Hormones/pharmacology , Indomethacin/pharmacology , Leukemia, Lymphoid/drug therapy , Leukemia, Lymphoid/pathology , Leukemia, Lymphoid/physiopathology , Male , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/pathology , Mammary Neoplasms, Experimental/physiopathology , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Neoplasms, Experimental/pathology , Neovascularization, Pathologic , Pregnancy , Pregnancy Complications, Neoplastic/pathology , Progesterone/metabolism , Progesterone/pharmacology , Receptors, Progesterone/metabolism , Teratoma/pathology , Teratoma/physiopathologyABSTRACT
La Resistencia Concomitante Antitumoral (RC) es el fenómeno según el cual un individuo portador de un tumor inhibe o retarda el crecimiento de implantes tumorales secundarios. Este fenómeno ha sido descripto en animales y en seres humanos y puede ser inducido tanto por tumores inmunogénicos como no-inmunogénicos. El estudio de la RC puede darnos indicios sobre mecanismos de control de las metástasis desde que las metástasis son, de hecho, implantes secundarios naturales desarrollados espontáneamente durante el crecimiento de un tumor primario. En este sentido la experiencia clínica y numerosos datos experimentales han revelado que la extirpación quirúrgica de un tumor puede ser seguida por una abrupta aceleración del crecimiento metastásico sugiriendo que, bajo ciertas circunstancias, un tumor puede ejercer un control inhibitorio sobre sus propias metástasis. En nuestro laboratorio hemos estudiado la RC asociada al crecimiento de numerosos tumores de ratón de diferente origen, tipo histológico e inmunogenicidad. Nuestros resultados demostraron que durante el crecimiento de un tumor primario se generan dos eventos temporalmente separados de RC. El primer evento es producido sólo por tumores inmunogénicos de pequeño tamaño (<500 mm3 ), es específico de tumor y es producido por mecanismos inmunológicos dependientes del timo. Por otro lado, el segundo evento de RC es inducido tanto por tumores inmunogénicos como no-inmunogénicos de gran tamaño (≥ 2000 mm3 ), no es específico de tumor, es timo independiente y correlaciona con la presencia de un factor sérico de bajo peso molecular que demostró tener capacidad para inhibir la proliferación de células tumorales tanto in vitro como in vivo. Cuando esta actividad antitumoral no estaba presente en el suero en nuestros modelos, los dos únicos casos estuvieron asociados a tumores altamente metastásicos el segundo evento de RC no se producía. Estos resultados sugieren una correlación directa entre la actividad sérica antitumoral, el segundo evento de RC y la capacidad para restringir el crecimiento metastásico.Aunque el primer evento de RC es producido, como dijimos arriba, por una respuesta inmunológica convencional mediada por células T, la naturaleza química del factor sérico asociado a la más universal manifestación de la RC (esto es, el segundo evento de RC), permaneció siendo un enigma por muchos años. En un trabajo reciente, identificamos ese factor sérico antitumoral como una mezcla de metatirosina y orto-tirosina, dos isómeros de tirosina que no están presentes en proteínas normales. Ambos isómeros fueron capaces de inhibir el crecimiento de diferentes tumores murinos que generan RC y restringieron el crecimiento de metástasis establecidas producidas por tumores que no generan RC pero son sensibles a la RC generada por otros tumores. A su vez, y tan significativo como lo anterior, estos efectos antitumorales se lograron sin ningún efecto colateral indeseado Una comprensión más profunda de los mecanismos moleculares asociados con el efecto antitumoral de estos isómeros de tirosina podría, eventualmente, ayudar a desarrollar métodos nuevos y menos tóxicos para combatir las enfermedades malignas; en particular para limitar el crecimiento acelerado de las metástasis después de la extirpación quirúrgica del tumor primario o después del padecimiento de traumas o estresores que pudieran despertar metástasis de su estado de tumor dormido.
Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants. This phenomenon has been described in human and animal systems and it can be generated by both immunogenic and non-immunogenic tumors. The relevance of CR to the mechanisms of metastases control has been highlighted by numerous observations showing that the removal of human and murine tumors may be followed by an abrupt increase in metastatic growth, suggesting that, upon certain circumstances, a primary tumor exerts a controlling action on its metastases which could be considered as secondary tumor implants developed spontaneously during the primary tumor growth. In our laboratory we have studied the CR induced by many murine tumors widely different in origin, histologic type and immunogenicity. Our results support the idea that during the primary tumor growth, there exist two temporally separate events of CR: the first one was exhibited only by small (<500 mm3 ) immunogenic tumors, it was tumor-specific and mediated by classical T-dependent immunological mechanisms. The second event was induced by both im munogenic and nonimmunogenic large (≥ 2000 mm3 ) tumors; it was non-tumor specific, thymus independent and correlated with the presence of a serum factor of low molecular weight that inhibited the in vitro and in vivo proliferation of tumor cells. When this anti-tumor serum activity was absent in our hands, the only two cases were associated with highly metastatic tumors the second event of CR did not exist, suggesting a direct correlation between the anti-tumor serum activity, the second event of CR and the ability to restrain metastatic growth. Although the mechanism associated with the first event of CR has, as said above, been elucidated as T celldependent, the molecular nature of the antitumor serum factor(s), which is at the root of the most universal manifestation of CR (that is, the second event of CR), remained an enigma for many years. In a recently published paper, we identified that antitumor serum factor(s) as a mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins. Both meta- and ortho-tyrosine inhibited the growth of different murine models of cancer that generate CR and could also block established spontaneous metastases produced by other murine models that do not generate CR but are very sensitive to the CR induced by other tumors. In addition, and most importantly, these anti-tumor effects were achieved without any collateral damage to the organism. A more profound understanding of the molecular mechanisms associated with the anti-tumor effects mediated by meta- and ortho-tyrosine could contribute to develop new and more harmless means to manage malignant diseases, especially by limiting the development of metastases that arise after resection of primary tumors or after other stressors that may promote the escape of metastases from dormancy.
Subject(s)
Humans , Tyrosine , Neoplasm Metastasis/prevention & control , Antineoplastic AgentsABSTRACT
Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants. This phenomenon has been described in human and animal systems and it can be generated by both immunogenic and non-immunogenic tumors. The relevance of CR to the mechanisms of metastases control has been highlighted by numerous observations showing that the removal of human and murine tumors may be followed by an abrupt increase in metastatic growth, suggesting that a primary tumor may exert a controlling action on its metastases which could be considered as secondary tumor implants developed spontaneously during the primary tumor growth. A more profound understanding of the different mechanisms claimed to be associated with the phenomenon of CR could contribute to develop new and more harmless means to manage malignant diseases, especially by limiting the development of metastases that arise after resection of primary tumors or after other stressors that may promote the escape of metastases from dormancy.